In collaboration with Principal Investigator Dr. Ana Pereira of Mt. Sinai Hospital and Rockefeller University, ADMdx has published the results of a Phase 2 study of the drug Riluzole in Alzheimer’s disease patients. Patients who received Riluzole for 6 months showed less decline in glucose metabolism, a measure of brain function, in key regions affected by Alzheimer’s disease than those who received placebo. ADMdx led the analysis of the FDG PET brain scans that measured glucose metabolism, which also showed a relationship to measures of cognition. The manuscript, published in the journal Brain, may be found at https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awab222/6305835?guestAccessKey=f5f0e25a-0b66-4625-b964-a955ec834d56.

Results of a study that used multiple types of brain imaging to better understand how the brain responds to changes that occur pre, during, and post menopause have been published in Nature. ADMdx provided image processing for the study led by Dr. Lisa Mosconi, Director of the Women’s Brain Initiative and Associate Director of the Alzheimer’s Prevention Clinic at Cornell Medical College. The manuscript, titled “Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition”, can be found at: https://www.nature.com/articles/s41598-021-90084-y .

February 15, 2021 – ADM Diagnostics (ADMdx) has published its findings from a study of the drug rasagiline in patients with Alzheimer’s disease. ADMdx performed the image analysis for this study, which was led by Dr. Jeffrey Cummings of the Lou Ruvo Center for Brain Health, Cleveland Clinic. ADMdx applied methods of measuring changes in brain activity measured using PET imaging of glucose metabolism.  The analyses revealed a treatment effect consistent with the monoamine inhibition properties of rasagiline. ADMdx also applied machine learning classification software to confirm the likelihood of Alzheimer’s disease in the study participants. Results matched the tau burden that was observed in these patients, measured using tau PET.

November 3, 2020 – ADM Diagnostics has received a patent on a novel method to detect and adjust for variability in PET scans.  PET scans of the brain can measure abnormal proteins such as amyloid or tau, and other characteristics.  In developing treatments for disease, it is very important to be able to measure small changes over time. This is often difficult due to technical “noise” in the scan.  ADMdx has developed a method to detect and correct for variability in the PET signal that allows for improved detection of the effects of disease and treatment.

September 30, 2020 – ADM Diagnostics has received a patent on a method that obtains information from a brain scan that would typically take much longer to measure. The first few minutes of a positron emission tomography (PET) scan contain information regarding brain blood flow and function.  Information regarding the amount of amyloid burden or other entities is not obtained until many minutes later.  To obtain both types of information requires scanning the patient for a long time or in two parts.  ADMdx’s method is able to obtain both types of information using the first 20 or less minutes. This has application in Alzheimer’s disease and in other brain disorders.

ADMdx will present findings regarding the presence of tau, an abnormal protein, in Alzheimer’s patients, at the Tau2020 conference to be held in Washington DC on February 12.  This work describes the diverse burden of tau in individuals with Alzheimer’s disease, and relationships to brain atrophy, glucose metabolism, age, gender, and clinical status.

ADMdx will present findings regarding relationships between tau, glucose metabolism, brain atrophy, and patient characteristics at the ADPD conference in April 2020. These analyses used a unique data set acquired through the Phase II study of the drug rasagiline in Alzheimer’s disease patients in collaboration with Dr. Jeffrey Cummings of the Cleveland Clinic. The data provides new insights regarding these biomarkers in Alzheimer’s disease.

Dawn Matthews, CEO, presented results of ADMdx’s analysis of image data for a Phase II clinical trial of the drug rasagiline in Alzheimer’s disease patients at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego.  The trial was led by Dr. Jeffrey Cummings of the Lou Ruvo Center for Brain Health at the Cleveland Clinic, in collaboration with the Alzheimer’s Disease Cooperative Study (ADCS) and the Alzheimer’s Drug Discovery Foundation (ADDF). ADMdx’s analysis of FDG PET data showed that rasagiline favorably affected glucose metabolism in frontostriatal regions of the brain, meeting the study’s primary endpoint. Clinical results also showed improvements in Quality of Life and in cognition associated with executive function.

Dawn Matthews, ADMdx CEO, was one of three speakers in an invited panel presentation at the Alzheimer’s Drug Discovery Foundation (ADDF) luncheon on November 1, 2019 in New York.  The panelists described the results of their studies, each focused on repurposing currently approved medications for use in Alzheimer’s disease. Ms. Matthews related the successful outcome of the Phase II clinical trial of rasagiline, led by Dr. Jeffrey Cummings of the Cleveland Clinic.  Image analyses were performed by ADMdx.

New results from ADMdx’s collaborative work on the Down syndrome Biomarker Initiative (DSBI) study led by Dr. Michael Rafii of the University of Southern California has been published.  These results show the correlation between imaging biomarkers and increases in NeuroFilament Light (NF-L), a blood-based marker of neurodegeneration. The manuscript is published in the journal Alzheimer’s & Dementia, titled “Plasma Neurofilament Light and Alzheimer’s Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)”.